Wegener's Granulomatosis (Renamed Granulomatosis with Polyangiitis) - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 8 min read ✅ Medically reviewed
Granulomatosis with Polyangiitis (Formerly Wegener’s Granulomatosis) – Complete Medical Guide

Granulomatosis with Polyangiitis (GPA) – A Comprehensive Guide

Overview

Granulomatosis with polyangiitis (GPA), historically known as Wegener’s granulomatosis, is a rare, systemic autoimmune disease characterized by inflammation of small‑ and medium‑sized blood vessels (vasculitis) and the formation of necrotic granulomas. The disease most often involves the respiratory tract (upper and lower) and the kidneys, but it can affect virtually any organ.

Who it affects: GPA can develop at almost any age but peaks between 40‑65 years. Slight male predominance has been reported (≈1.2 : 1). It occurs worldwide, without strong ethnic predilection.

Prevalence & incidence: According to the United States Centers for Disease Control and Prevention (CDC) and the European Vasculitis Society, GPA affects roughly 3–10 people per million annually, with a cumulative prevalence of about 20–35 per million in the general population.1 The rarity underscores the importance of early recognition.

Symptoms

GPA often begins with nonspecific systemic symptoms, followed by organ‑specific signs. The classic triad involves the upper airway, lungs, and kidneys, but many patients experience additional manifestations.

Constitutional (systemic) symptoms

  • Fever – low‑grade or intermittent.
  • Fatigue – profound, often out of proportion to activity level.
  • Weight loss – unintentional, several kilograms over weeks‑months.
  • Night sweats – soaking sweats without obvious cause.
  • Muscle aches (myalgias) and joint pain (arthralgias) without swelling.

Upper respiratory tract

  • Chronic sinusitis or recurrent sinus infections.
  • Nasal crusting, ulceration, or bleeding (epistaxis).
  • Otitis media or mastoiditis.
  • Hoarseness or sore throat.
  • Polyps or mass‑like lesions in the nasopharynx.
**Lower respiratory tract**
  • Persistent cough (dry or productive).
  • Hemoptysis (coughing up blood).
  • Shortness of breath, especially on exertion.
  • Chest pain that may be pleuritic.
  • Radiographic nodules, cavitary lesions, or diffuse infiltrates.
**Renal (kidney) involvement**
  • Hematuria (blood in urine) – often microscopic.
  • Proteinuria (protein in urine).
  • Rapidly progressive glomerulonephritis – can lead to renal failure if untreated.
  • Elevated creatinine and decreasing urine output.
**Other organ systems**
  • Skin: palpable purpura, livedo reticularis, ulcerations.
  • Eyes: scleritis, conjunctivitis, or orbital inflammation.
  • Peripheral nerves: mononeuritis multiplex – sudden weakness or numbness in isolated nerve distributions.
  • Ear: conductive hearing loss from middle‑ear disease.
  • Gastrointestinal: abdominal pain, bleeding, or perforation (rare).
  • Cardiac: pericarditis, myocarditis, or coronary vasculitis (uncommon).

Causes and Risk Factors

GPA is an autoimmune vasculitis**; the exact trigger remains unknown, but research points to a combination of genetic susceptibility and environmental factors.

Immunologic mechanisms

  • Production of anti‑neutrophil cytoplasmic antibodies (ANCA), most commonly c‑ANCA** directed against proteinase‑3 (PR3).
  • ANCA‑mediated activation of neutrophils leads to endothelial damage, granuloma formation, and vessel necrosis.

Genetic predisposition

  • Strong association with HLA‑DPB1*0401 and HLA‑DQ variants.2
  • Family clustering is rare but documented.

Environmental & occupational triggers

  • Silica dust exposure (e.g., mining, construction) modestly elevates risk.
  • Chronic nasal colonization with Staphylococcus aureus – may stimulate autoimmunity.
  • Medications such as propylthiouracil and hydralazine have been linked to ANCA‑positive vasculitis, though usually drug‑induced rather than classic GPA.

Who is at higher risk?

  • Adults age 40‑65, especially males.
  • Individuals with a history of chronic sinus disease or recurrent respiratory infections.
  • Workers with prolonged silica exposure.
  • People who are ANCA‑positive without symptoms (rare; requires monitoring).

Diagnosis

Because early symptoms mimic common infections, a high index of suspicion is essential. Diagnosis integrates clinical presentation, laboratory data, imaging, and tissue pathology.

Laboratory tests

  • ANCA testing – c‑ANCA (PR3‑ANCA) is positive in 70‑90 % of active GPA cases.3
  • Complete blood count (CBC) – may reveal anemia or leukocytosis.
  • Erythrocyte sedimentation rate (ESR) and C‑reactive protein (CRP) – elevated, reflecting inflammation.
  • Renal panel – serum creatinine, BUN, electrolytes.
  • Urinalysis – hematuria, proteinuria, red‑cell casts.

Imaging studies

  • Chest X‑ray – may show nodules, cavitations, or infiltrates.
  • High‑resolution CT (HRCT) of the chest – more sensitive for nodules, ground‑glass opacities, and airway disease.
  • Sinus CT – assesses chronic sinusitis, bony destruction, or masses.
  • Renal ultrasound if kidney involvement is suspected.

Biopsy (gold standard)

Obtaining tissue from an affected organ confirms vasculitis and granuloma formation. Common sites include:

  • Nasopharyngeal mucosa or sinus tissue.
  • Kidney (via percutaneous renal biopsy) – shows necrotizing glomerulonephritis.
  • Skin lesions (purpura) – can demonstrate leukocytoclastic vasculitis.
  • Lung tissue (via bronchoscopy or surgical biopsy) – reveals necrotizing granulomas.

Histopathology, combined with ANCA positivity, yields a >90 % diagnostic accuracy.4

Classification criteria

The 2022 ACR/EULAR GPA classification criteria assign points for:

  • Positive PR3‑ANCA (5 points)
  • Upper airway involvement (2 points)
  • Kidney involvement (2 points)
  • Chest imaging showing nodules/cavities (2 points)
  • Granulomatous inflammation on biopsy (3 points)

A total score ≥5 classifies the patient as GPA with >90 % sensitivity and specificity.5

Treatment Options

Therapy aims to induce remission quickly, then maintain disease control while minimizing drug toxicity. Treatment is usually managed by rheumatologists, nephrologists, and pulmonologists working together.

Induction therapy (remission‑inducing)

  • High‑dose glucocorticoids – oral prednisone 1 mg/kg/day (max 60 mg) or IV methylprednisolone 500‑1000 mg daily for 3 days in severe cases.
  • Rituximab – anti‑CD20 monoclonal antibody, 375 mg/m² weekly for 4 weeks or 1000 mg on days 0 and 14; preferred for patients with severe renal disease or when cyclophosphamide is contraindicated.6
  • Cyclophosphamide – oral (2 mg/kg/day) or IV pulse (15 mg/kg every 2‑3 weeks) for 3‑6 months; effective but carries long‑term risks (infertility, bladder toxicity).
  • Plasma exchange (PLEX) – considered for rapidly progressive glomerulonephritis or severe pulmonary hemorrhage (usually 7 exchanges over 14 days). Recent trials (PEXIVAS) suggest limited mortality benefit but may aid kidney preservation in select patients.7

Maintenance therapy (preventing relapse)

  • Azathioprine 2‑2.5 mg/kg/day.
  • Mycophenolate mofetil 1‑1.5 g twice daily (alternative for those intolerant to azathioprine).
  • Rituximab 500 mg IV on days 0 and 14, then every 6 months for up to 2 years (based on PR3‑ANCA positivity).
  • Low‑dose prednisone (≤5 mg/day) is often continued for the first 12‑18 months, then tapered.

Adjunctive measures

  • Trimethoprim‑sulfamethoxazole (TMP‑SMX) prophylaxis – reduces Staphylococcus aureus colonization and decreases relapse risk in PR3‑ANCA patients.8
  • Vaccinations (influenza, pneumococcal, COVID‑19) – essential before starting immunosuppression.
  • Bone health: calcium, vitamin D, and bisphosphonates if on long‑term steroids.
  • Fertility counseling & gonadotropin‑releasing hormone (GnRH) agonists for patients receiving cyclophosphamide.

Lifestyle modifications

  • Smoking cessation – improves pulmonary outcomes.
  • Balanced diet rich in fruits, vegetables, lean protein; limit sodium if kidney disease is present.
  • Regular, moderate exercise as tolerated to maintain muscle mass and cardiovascular health.
  • Avoidance of silica or dust exposure (use protective masks).

Living with Granulomatosis with Polyangiitis

Managing GPA is a lifelong partnership between the patient, specialists, and primary care provider.

Monitoring & follow‑up

  • Clinic visits every 1‑3 months during induction; every 3‑6 months in maintenance.
  • Laboratory panel each visit: CBC, ESR/CRP, renal function, urinalysis, ANCA titer (optional – trends may help anticipate relapse).
  • Imaging (chest X‑ray or sinus CT) annually or if new respiratory symptoms arise.

Medication adherence

Missing doses of immunosuppressants can precipitate relapse, which may be organ‑threatening. Use pill organizers, smartphone reminders, or involve a caregiver.

Managing side effects

  • Glucocorticoid‑related: mood changes, hyperglycemia, osteoporosis – discuss prophylaxis with your doctor.
  • Cyclophosphamide: regular urine cytology and bladder scans.
  • Rituximab: monitor for infusion reactions and infections; receive immunoglobulin replacement if hypogammaglobulinemia develops.

Psychosocial support

  • Connect with patient advocacy groups such as the Vasculitis Foundation or local support circles.
  • Consider counseling or cognitive‑behavioral therapy for anxiety/depression, common in chronic autoimmune disease.
  • Address work‑related issues early; many patients can continue employment with reasonable accommodations.

Reproductive health

  • Discuss family planning before initiating cyclophosphamide; sperm banking for men and egg/embryo freezing for women are options.
  • Pregnancy is possible but requires careful coordination; disease should be in remission and glucocorticoids are the preferred agents.

Prevention

Because GPA’s exact cause is unknown, primary prevention is limited. However, steps that may reduce risk or severity include:

  • Avoidance of occupational silica dust; use respirators in high‑risk settings.
  • Prompt treatment of chronic sinus infections and nasal carriage of Staphylococcus aureus.
  • Regular medical check‑ups for individuals with known ANCA positivity or a family history of vasculitis.
  • Vaccination against common respiratory pathogens to lower infection‑driven immune activation.

Complications

If left untreated or inadequately controlled, GPA can lead to life‑threatening organ damage.

  • Renal failure – progressive glomerulonephritis may require dialysis or transplantation.
  • Severe pulmonary hemorrhage – can cause respiratory failure.
  • Upper airway obstruction – granulomatous tissue can block nasal passages or cause subglottic stenosis.
  • Peripheral neuropathy – may become permanent if nerve ischemia is extensive.
  • Vascular aneurysms – rare but possible in larger arteries.
  • Infections – immunosuppression increases risk of bacterial, fungal, and viral infections.
  • Secondary malignancies – long‑term cyclophosphamide exposure raises bladder cancer risk.
  • Osteoporosis and fractures – due to chronic steroid use.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department immediately if you experience any of the following:
  • Sudden, severe shortness of breath or coughing up large amounts of blood.
  • Rapidly worsening kidney function (e.g., decreased urine output, swelling of legs/face, abrupt rise in blood pressure).
  • Severe, unilateral facial or neck swelling that threatens airway obstruction.
  • New onset of severe, persistent headache with visual changes or confusion (possible CNS involvement).
  • High fever (>39 °C / 102 °F) with chills and feeling very ill despite antibiotics.
  • Signs of a serious infection: painful, red skin lesions, rapidly spreading rash, or uncontrolled diarrhea.

These symptoms may signal organ‑life‑threatening complications and require rapid intervention.

**Sources**:
1. Centers for Disease Control and Prevention. Vasculitis Fact Sheet.
2. Liao Z et al. HLA‑DPB1 and GPA susceptibility. Nat Rev Rheumatol. 2020.
3. Mayo Clinic. Granulomatosis with polyangiitis (GPA) – Diagnosis & treatment.
4. Cleveland Clinic. Granulomatosis with Polyangiitis – Overview.
5. ACR/EULAR 2022 Classification Criteria for GPA. Ann Rheum Dis. 2022.
6. Stone JH et al. Rituximab versus cyclophosphamide for ANCA‑associated vasculitis. NEJM. 2010.
7. Walsh M et al. Plasma exchange and outcomes in severe ANCA‑associated vasculitis (PEXIVAS). NEJM. 2020.
8. CDC. Antibiotic prophylaxis guidelines for immunocompromised patients.

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References